Philip Van Kerrebroeck - Academia.edu (original) (raw)

Uploads

Papers by Philip Van Kerrebroeck

Research paper thumbnail of The standardisation of terminology in nocturia: Report from the standardisation sub-committee of the International Continence Society

Neurourology and Urodynamics, 2002

Nocturia is the complaint that the individual has to wake at night one or more times to void. (In... more Nocturia is the complaint that the individual has to wake at night one or more times to void. (International Continence Society De¢nition from ICS Standardisation of Terminology Report 2002). Nocturia is a condition that has only recently begun to be recognised as a clinical entity in its own ...

Research paper thumbnail of Reviewing the ICS 2002 terminology report: The ongoing debate

Neurourology and Urodynamics, 2006

Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. and Sand, P.(2006), Re... more Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. and Sand, P.(2006), Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourology and Urodynamics, 25: 293. doi: 10.1002/nau. 20251

Research paper thumbnail of Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms

BJU International, 2014

The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including s... more The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post-micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3 -adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large-scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health-related quality-of-life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.

Research paper thumbnail of The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society

American Journal of Obstetrics and Gynecology, 2002

This report presents de¢nitions of the symptoms, signs, urodynamic observations and conditions as... more This report presents de¢nitions of the symptoms, signs, urodynamic observations and conditions associated with lower urinary tract dysfunction (LUTD) and urodynamic stu-dies (UDS), for use in all patient groups from children to the elderly. The de¢nitions restate or update those ...

Research paper thumbnail of Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women

American Journal of Obstetrics and Gynecology, 2003

The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the ... more The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in women. Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period. After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks. In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72). For desmopressin, 33 (46%) patients had a 50% or greater reduction in nocturnal voids against baseline levels compared with 5 (7%) patients receiving placebo (P<.0001). The mean number of nocturnal voids, duration of sleep until the first nocturnal void, nocturnal diuresis, and ratios of nocturnal per 24 hours and nocturnal per daytime urine volumes changed significantly in favor of desmopressin versus placebo (P<.0001). In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported. Two deaths occurred, although neither could be directly associated with the study drug. Oral desmopressin is an effective and well-tolerated treatment for nocturia in women.

Research paper thumbnail of Thinking beyond the bladder: antidiuretic treatment of nocturia

International Journal of Clinical Practice, 2010

Research paper thumbnail of The standardisation of terminology in nocturia: Report from the standardisation sub-committee of the International Continence Society

Neurourology and Urodynamics, 2002

Nocturia is the complaint that the individual has to wake at night one or more times to void. (In... more Nocturia is the complaint that the individual has to wake at night one or more times to void. (International Continence Society De¢nition from ICS Standardisation of Terminology Report 2002). Nocturia is a condition that has only recently begun to be recognised as a clinical entity in its own ...

Research paper thumbnail of Reviewing the ICS 2002 terminology report: The ongoing debate

Neurourology and Urodynamics, 2006

Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. and Sand, P.(2006), Re... more Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. and Sand, P.(2006), Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourology and Urodynamics, 25: 293. doi: 10.1002/nau. 20251

Research paper thumbnail of Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms

BJU International, 2014

The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including s... more The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post-micturition symptoms. Although treatment of male LUTS tends to focus on voiding symptoms, patients typically find storage symptoms the most bothersome. The core storage symptom is urgency, which drives the other main storage symptoms of increased daytime frequency, nocturia and incontinence. Although several validated questionnaires have been widely used to study urgency, few measure the two important storage parameters, urgency and frequency, in a single assessment. The total urgency and frequency score (TUFS) is a new validated tool that captures both variables and is derived from the Patient Perception of Intensity of Urgency Scale, which has been validated in patients with OAB and LUTS. The TUFS was first validated in OAB in the phase IIa BLOSSOM study, which was designed to assess the efficacy and safety of mirabegron, a β3 -adrenoceptor agonist, in 260 patients. The responsiveness of the TUFS to treatment has been confirmed in a further three large-scale randomized controlled trials of solifenacin in patients with OAB or LUTS. Changes in TUFS from baseline to end of treatment were consistent with changes in micturition diary variables in all four studies. Furthermore, the TUFS was significantly correlated with several health-related quality-of-life variables in the phase III NEPTUNE study. Thus, the TUFS appears to be useful for assessing improvements in major storage symptoms (urgency and frequency) in clinical trials.

Research paper thumbnail of The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society

American Journal of Obstetrics and Gynecology, 2002

This report presents de¢nitions of the symptoms, signs, urodynamic observations and conditions as... more This report presents de¢nitions of the symptoms, signs, urodynamic observations and conditions associated with lower urinary tract dysfunction (LUTD) and urodynamic stu-dies (UDS), for use in all patient groups from children to the elderly. The de¢nitions restate or update those ...

Research paper thumbnail of Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women

American Journal of Obstetrics and Gynecology, 2003

The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the ... more The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in women. Women aged 18 years or older with nocturia (>or=2 voids per night with a nocturia index score >1) received desmopressin (0.1 mg, 0.2 mg, or 0.4 mg) during a 3-week dose-titration period. After a 1-week washout period, patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks. In double-blind phase, 144 patients were randomly assigned to groups (desmopressin, n=72; placebo, n=72). For desmopressin, 33 (46%) patients had a 50% or greater reduction in nocturnal voids against baseline levels compared with 5 (7%) patients receiving placebo (P<.0001). The mean number of nocturnal voids, duration of sleep until the first nocturnal void, nocturnal diuresis, and ratios of nocturnal per 24 hours and nocturnal per daytime urine volumes changed significantly in favor of desmopressin versus placebo (P<.0001). In the dose-titration phase headache (22%), nausea (8%), and hyponatremia (6%) were reported. Two deaths occurred, although neither could be directly associated with the study drug. Oral desmopressin is an effective and well-tolerated treatment for nocturia in women.

Research paper thumbnail of Thinking beyond the bladder: antidiuretic treatment of nocturia

International Journal of Clinical Practice, 2010